Download PDF
Thromb Haemost 2021; 121(01): 036-045
DOI: 10.1055/s-0040-1715840
Coagulation and Fibrinolysis

Recombinant Thrombomodulin in Disseminated Intravascular Coagulation Associated with Stage IV Solid Tumors: A Nationwide Observational Study in Japan

Kohei Taniguchi‡   ∗
1   Translational Research Program, Osaka Medical College, Osaka, Japan
,
Hiroyuki Ohbe  ‡   ∗
2   Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
,
Kazuma Yamakawa 
3   Department of Emergency Medicine, Osaka Medical College, Osaka, Japan
,
Hiroki Matsui
2   Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
,
Kiyohide Fushimi
4   Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan
,
Hideo Yasunaga
2   Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
› Author Affiliations Funding This work was supported by grants from the Ministry of Health, Labor and Welfare, Japan (19AA2007 and H30-Policy-Designated-004) and the Ministry of Education, Culture, Sports, Science and Technology, Japan (17H04141).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective The terminal stage of solid tumors sometimes induces disseminated intravascular coagulation (DIC); however, no useful therapeutic strategies have been established. This study investigated the relationship between mortality and recombinant human soluble thrombomodulin (rTM) therapy for patients with DIC associated with stage IV solid tumors using a large nationwide inpatient database.

Methods Using the Japanese Diagnosis Procedure Combination Inpatient Database, patients with stage IV solid tumors who developed DIC were identified. Those who received rTM within 3 days of admission were included in the treatment group; the remaining were included in the control group. The primary outcome was the 28-day in-hospital mortality.

Results Of 25,299 eligible patients, 1 to 4 propensity score matching was used to select 1,979 rTM users and 7,916 nonusers. There was no significant difference in the 28-day mortality (control vs. rTM: 37.4% vs. 34.3%; hazard ratio, 0.95; 95% confidence interval [CI], 0.88–1.04) and critical bleeding rate (control vs. rTM: 3.7% vs. 3.8%; odds ratio, 1.04; 95% CI, 0.75–1.42) between groups. Subgroup analyses showed that the 28-day mortality rate among patients with colorectal and gynecological cancer was significantly lower in the rTM than in the control group (p for interaction 0.033 and 0.010, respectively).

Conclusion Although we identified a possibly beneficial association between rTM administration and mortality in specific populations of patients with colorectal and gynecological cancer, no such association was found when considering the entire cohort of patients with DIC associated with stage IV solid tumors.

Keywords

disseminated intravascular coagulation - anticoagulant drugs - thrombomodulin - solid tumor - recombinant human soluble thrombomodulin

∗ These authors contributed equally to this work.


Supplementary Material



Publication History

Received: 10 April 2020

Accepted: 14 July 2020

Article published online:
09 September 2020

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25 (02) 173-182
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341 (08) 586-592
    CrossrefPubMedGoogle Scholar
  • 3 Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers 2016; 2: 16037
    Google Scholar
  • 4 Okajima K, Sakamoto Y, Uchiba M. Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases. Am J Hematol 2000; 65 (03) 215-222
    CrossrefPubMedGoogle Scholar
  • 5 Murata A, Okamoto K, Mayumi T, Muramatsu K, Matsuda S. The recent time trend of outcomes of disseminated intravascular coagulation in Japan: an observational study based on a national administrative database. J Thromb Thrombolysis 2014; 38 (03) 364-371
    CrossrefPubMedGoogle Scholar
  • 6 Wada H, Thachil J, Di Nisio M. et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; DOI: 10.1111/jth.12155.
    CrossrefPubMedGoogle Scholar
  • 7 Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care 2014; 2 (01) 15
    CrossrefPubMedGoogle Scholar
  • 8 Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 2001; 86 (03) 828-833
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Tamura K, Saito H, Asakura H. et al. Recombinant human soluble thrombomodulin (thrombomodulin alfa) to treat disseminated intravascular coagulation in solid tumors: results of a one-arm prospective trial. Int J Clin Oncol 2015; 20 (04) 821-828
    CrossrefPubMedGoogle Scholar
  • 10 Yamakawa K, Fujimi S, Mohri T. et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011; 15 (03) R123
    CrossrefPubMedGoogle Scholar
  • 11 Ito T, Kakihana Y, Maruyama I. Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases. Expert Opin Ther Targets 2016; 20 (02) 151-158
    CrossrefPubMedGoogle Scholar
  • 12 Ito T, Thachil J, Asakura H, Levy JH, Iba T. Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential. Crit Care 2019; 23 (01) 280
    CrossrefPubMedGoogle Scholar
  • 13 Saito H, Maruyama I, Shimazaki S. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5 (01) 31-41
    CrossrefPubMedGoogle Scholar
  • 14 Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. Thromb Haemost 2019; 119 (01) 56-65
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Martí-Carvajal AJ, Anand V, Solà I. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database Syst Rev 2015; (06) CD008562
    PubMedGoogle Scholar
  • 16 Ouchi K, Takahashi S, Chikamatsu S. et al. Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors. Int J Clin Oncol 2018; 23 (04) 790-798
    CrossrefPubMedGoogle Scholar
  • 17 Yasunaga H. Real world data in Japan: chapter ii the diagnosis procedure combination database. Ann Clin Epidemiol 2019; 1: 76-79
    CrossrefPubMedGoogle Scholar
  • 18 Yamana H, Horiguchi H, Fushimi K, Yasunaga H. Comparison of procedure-based and diagnosis-based identifications of severe sepsis and disseminated intravascular coagulation in administrative data. J Epidemiol 2016; 26 (10) 530-537
    CrossrefPubMedGoogle Scholar
  • 19 Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict stroke outcome–reintroduction of Japan Coma Scale: a cohort study. BMJ Open 2013; 3 (04) e002736
    CrossrefPubMedGoogle Scholar
  • 20 Quan H, Li B, Couris CM. et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173 (06) 676-682
    Google Scholar
  • 21 Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29 (07) 1303-1310
    CrossrefPubMedGoogle Scholar
  • 22 Griswold ME, Localio AR, Mulrow C. Propensity score adjustment with multilevel data: setting your sites on decreasing selection bias. Ann Intern Med 2010; 152 (06) 393-395
    CrossrefPubMedGoogle Scholar
  • 23 Rosenbaum PR, Rubin DB. The bias due to incomplete matching. Biometrics 1985; 41 (01) 103-116
    CrossrefPubMedGoogle Scholar
  • 24 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28 (25) 3083-3107
    CrossrefPubMedGoogle Scholar
  • 25 Leuven ESianesi B. PSMATCH2: Stata Module to Perform Full Mahalanobis and Propensity Score Matching, Common Support Graphing, and Covariate Imbalance Testing. Boston, MA: Boston College Department of Economics; 2003
    Google Scholar
  • 26 Miglioretti DL, Heagerty PJ. Marginal modeling of nonnested multilevel data using standard software. Am J Epidemiol 2007; 165 (04) 453-463
    CrossrefPubMedGoogle Scholar
  • 27 Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood 2014; 124 (10) 1553-1562
    CrossrefPubMedGoogle Scholar
  • 28 Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34 (01) 107-125
    CrossrefPubMedGoogle Scholar
  • 29 Liu L, Yang M, Kang R. et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011; 25 (01) 23-31
    CrossrefPubMedGoogle Scholar
  • 30 He SJ, Cheng J, Feng X, Yu Y, Tian L, Huang Q. The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget 2017; 8 (38) 64534-64550
    CrossrefPubMedGoogle Scholar
  • 31 Shirai Y, Uwagawa T, Shiba H. et al. Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation. Surgery 2017; 161 (06) 1675-1682
    CrossrefPubMedGoogle Scholar
  • 32 Minami T, Takeda M, Sata M. et al. Thrombomodulin alfa prevents oxaliplatin-induced neuropathic symptoms through activation of thrombin-activatable fibrinolysis inhibitor and protein C without affecting anti-tumor activity. Eur J Pharmacol 2020; 880: 173196
    CrossrefPubMedGoogle Scholar
  • 33 Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care 2014; 2 (01) 20
    CrossrefPubMedGoogle Scholar
  • 34 Kashiwagi S, Asano Y, Takahashi K. et al. Clinical outcomes of recombinant human-soluble thrombomodulin treatment for disseminated intravascular coagulation in solid tumors. Anticancer Res 2019; 39 (05) 2259-2264
    CrossrefPubMedGoogle Scholar
  • 35 Lee AY. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 2002; 28 (03) 137-140
    CrossrefPubMedGoogle Scholar
  • 36 Kawasugi K, Wada H, Hatada T. Japanese Society of Thrombosis Hemostasis/DIC Subcommittee. et al; Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res 2011; 128 (02) 186-190
    CrossrefPubMedGoogle Scholar
  • 37 Taylor Jr FB, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 (05) 1327-1330
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Gando S, Iba T, Eguchi Y. Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. et al; A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34 (03) 625-631
    CrossrefPubMedGoogle Scholar
  • 39 Yamakawa K, Ogura H, Fujimi S. et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013; 39 (04) 644-652
    CrossrefPubMedGoogle Scholar
  • 40 Yoshimura J, Yamakawa K, Ogura H. et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Crit Care 2015; 19: 78
    CrossrefPubMedGoogle Scholar